account_id none on file
legal_name Bicycle Therapeutics PLC
ticker BCYC
cik 1761612
domain bicycletherapeutics.com
linkedin_company_url https://www.linkedin.com/company/bicycle-therapeutics
entry_point_account_id none on file
name Bicycle Therapeutics plc
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 19 executives 3 family 0
why_nownone on file
callsnone on file
filings
accounting, auditing, tax and consulting services, insurance, travel expenses and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs.
filing / Jul 30, 2026 / receipt
Together, the workforce reduction and strategic reprioritization are expected to reduce our annual operating expenses by approximately 50% based on our current plans.
filing / Jul 30, 2026 / receipt
We expect the workforce reduction to be substantially completed by the end of 2026, and that we will incur aggregate charges of approximately $6.5 million, representing cash expenditure for severance and other employee termination benefits, of which $1.3 million and $5.5 million was recognized during the three and six months ended June 30, 2026, respectively.
filing / Jul 30, 2026 / receipt
We expect that our expenses and capital requirements will decrease in the near term as a result of our cost saving initiatives and our strategic reprioritization announced in March 2026.
filing / Jul 30, 2026 / receipt
We expect that our research and development expenses will decrease in the near term as a result of our cost saving initiatives and our strategic reprioritization announced in March 2026.
filing / Jul 30, 2026 / receipt
Further, because of our hybrid work environment, information that is normally protected, including company confidential information, may be less secure.
filing / Jul 30, 2026 / receipt
accounting, auditing, tax and consulting services, insurance, travel expenses and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs.
filing / Apr 30, 2026 / receipt
Together, the workforce reduction and strategic reprioritization are expected to reduce our annual operating expenses by approximately 50% based on our current plans.
filing / Apr 30, 2026 / receipt
We expect the workforce reduction to be substantially completed by the end of 2026, and that we will incur aggregate charges, representing cash expenditure for severance and other employee termination benefits, of approximately $7.2 million, $4.2 million of which was recognized during the three months ended March 31, 2026.
filing / Apr 30, 2026 / receipt
We expect that our expenses and capital requirements will decrease in the near term as a result of our cost saving initiatives and our strategic reprioritization announced in March 2026.
filing / Apr 30, 2026 / receipt
We expect that our research and development expenses will decrease in the near term as a result of our cost saving initiatives and our strategic reprioritization announced in March 2026.
filing / Apr 30, 2026 / receipt
Further, because of our hybrid work environment, information that is normally protected, including company confidential information, may be less secure.
filing / Apr 30, 2026 / receipt
executives
| Alethia Young | Chief Financial Officer | - | receipt |
| Alistair Milnes | Chief Corporate Development Officer | - | receipt |
| Travis Thompson | Chief Accounting Officer (CAO) | receipt |
familynone on file
upcoming
| 2026-10-29 | earnings call | scheduled | ir |
changes
| 2026-02-03 | Chief Financial Officer, appointed | sec_8k |
| 2023-06-23 | Chief Accounting Officer, appointed | sec_8k |
| 2023-06-23 | Chief Financial Officer, appointed | sec_8k |
| 2022-01-05 | Chief Operating Officer, appointed | sec_8k |
mcp_package_hint
slug bicycle-therapeutics-plc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$